J.W. Cole Advisors, Inc. Biocryst Pharmaceuticals Inc Transaction History

J.W. Cole Advisors, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	SELL	$4.89 - $7.65 $36,675 - $57,375	-7,500 Reduced 37.31%	12,600 $64,000
Q4 2023 Jan 31, 2024	BUY	$4.98 - $6.77 $996 - $1,354	200 Added 1.01%	20,100 $120,000
Q3 2023 Oct 24, 2023	SELL	$6.71 - $7.92 $15,433 - $18,216	-2,300 Reduced 10.36%	19,900 $140,000
Q3 2022 Oct 31, 2022	SELL	$10.79 - $14.81 $1,079 - $1,481	-100 Reduced 0.45%	22,200 $280,000
Q2 2022 Jul 27, 2022	SELL	$7.89 - $17.88 $67,065 - $151,980	-8,500 Reduced 27.6%	22,300 $236,000
Q1 2022 Jun 10, 2022	SELL	$11.56 - $19.76 $5.4 Million - $9.23 Million	-466,956 Reduced 93.81%	30,800 $501,000
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $5.33 Million - $9.11 Million	460,956 Added 1252.6%	497,756 $34,000
Q4 2021 Jan 25, 2022	BUY	$11.18 - $15.46 $8,217 - $11,363	735 Added 2.04%	36,800 $510,000
Q3 2021 Oct 26, 2021	BUY	$14.21 - $17.65 $222,599 - $276,487	15,665 Added 76.79%	36,065 $547,000
Q2 2021 Aug 06, 2021	SELL	$9.5 - $17.24 $19,000 - $34,480	-2,000 Reduced 8.93%	20,400 $323,000
Q4 2020 Feb 12, 2021	BUY	$3.37 - $8.61 $75,488 - $192,864	22,400 New	22,400 $167,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of J.W. Cole Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on J.W. Cole Advisors, Inc. with notifications on news.